Halozyme Therapeutics reported second quarter 2026 financial results, posting total revenue of $481 million, a 48% year-over-year increase driven by royalty revenue growth to $307.7 million and product sales. The company raised its full-year 2026 guidance, projecting total revenue between $1.835 billion and $1.910 billion, non-GAAP diluted EPS of $8.65 to $9.00, and adjusted EBITDA of $1.225 billion to $1.280 billion. Halozyme also announced five new collaboration agreements for its ENHANZE and Hypercon technologies with partners including Vertex, GSK, Incyte, and Oruka. Additionally, the company repurchased 4.8 million shares for $332.8 million in the quarter under its existing share repurchase programs. Halozyme Therapeutics is a biopharmaceutical company that develops drug delivery technologies to facilitate subcutaneous administration of therapies.
